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Background: Knowledge about the effects of GH treatment on cognitive functioning in children
with Prader-Willi syndrome (PWS) is limited.
Methods: Fifty prepubertal children aged 3.5 to 14 yr were studied in a randomized controlled GH
trial during 2 yr, followed by a longitudinal study during 4 yr of GH treatment. Cognitive func-
tioningwasmeasuredbiennially by short formsof theWPPSI-R orWISC-R, dependingonage. Total
IQ (TIQ) score was estimated based on two subtest scores.
Results:During the randomized controlled trial, mean SD scores of all subtests andmean TIQ score
remained similar compared to baseline in GH-treated children with PWS, whereas in untreated
controls mean subtest SD scores and mean TIQ score decreased and became lower compared to
baseline. This decline was significant for the Similarities (P  0.04) and Vocabulary (P  0.03)
subtests. After 4 yr of GH treatment, mean SD scores on the Similarities and Block design subtests
were significantly higher than at baseline (P  0.01 and P  0.03, respectively), and scores on
Vocabulary and TIQ remained similar compared to baseline. At baseline, children with a maternal
uniparental disomy had a significantly lower score on the Block design subtest (P  0.01) but a
larger increment on this subtest during 4 yr of GH treatment than children with a deletion. Lower
baseline scores correlated significantly with higher increases in Similarities (P  0.04) and Block
design (P  0.0001) SD scores.
Conclusions:Our study shows that GH treatment prevents deterioration of certain cognitive skills
in children with PWS on the short term and significantly improves abstract reasoning and visu-
ospatial skills during 4 yr of GH treatment. Furthermore, children with a greater deficit had more
benefit from GH treatment. (J Clin Endocrinol Metab 97: 2307–2314, 2012)
Prader-Willi syndrome (PWS) is a neurodevelopmentaldisorder resulting from the absence of expression of
paternally expressed genes locatedon chromosome15at the
locus q11-q13 caused by paternal deletion, maternal unipa-
rental disomy (mUPD), imprinting errors, or paternal chro-
mosomal translocation (1). PWS is characterized by a num-
ber of signs and symptoms, including muscular hypotonia,
hypogonadism,short stature,obesity,psychomotordelay,neu-
robehavioral abnormalities, and cognitive impairment (2).
Long-termcontinuousGHtreatment is an effective and
safe treatment for childrenwith PWS (3, 4). Previously,we
showed that 1 yr of GH treatment significantly improved
mental andmotor development in infantswith PWS, com-
pared with randomized controls (5).
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There is little information about the effect of GH treat-
ment on cognitive development in infants with PWS (5, 6)
and no information about this effect in children with PWS
above 3 yr of age beyond a period of 6 months. Studies in
children born small for gestational age showed a significant
increase in total IQ (TIQ) score during 9 yr of GH therapy,
mainlydue to increased scores in theperformancearea, com-
pared with a Dutch reference population (7, 8). Recently, a
study in adolescents with Down syndrome demonstrated a
positive, although not significant, effect of GH treatment on
cognitive function in 12GH-treated patients comparedwith
10controls15yrafter itsdiscontinuation.GHtreatmentwas
started at 7 yr of age and continued for 3 yr (9).
In our randomized controlledGH trial, we investigated
the effect of GH treatment on cognitive functioning in
children with PWS. Furthermore, we studied cognitive
functioning during 4 yr of continuousGH treatment in the
PWS cohort study and the effects of age at the start of GH
treatment, serum IGF-I level, head circumference, and ge-
notype on cognitive functioning. We hypothesized that
long-termGH treatment has a positive effect onTIQ score
and especially on performance, i.e. nonverbal abilities.
Patients and Methods
Patients
Fifty prepubertal children with PWS were included. All par-
ticipants fulfilled the following inclusion criteria: 1) genetically
confirmed diagnosis of PWS; 2) age between 3 and 12 yr (girls)
or 14 yr (boys) at start of study; 3) bone age less than 14 yr (girls)
or 16 yr (boys); and 4) prepubertal at start of study, defined as
Tanner breast stage of 2 or less for girls and testicular volume less
than 4 ml for boys (10). Children were regularly seen by a phys-
iotherapist and speech therapist. The activity level of all children
was standardized at 3months before the start of the study. Com-
pliance to exercise was evaluated by the research nurse in close
collaboration with the physiotherapist and speech therapist.
Design
Randomized controlled trial (RCT)
In April 2002, a multicenter RCT was started in 50 children
with PWS, investigating the effects of GH treatment vs. no GH
treatment on growth, body composition, activity level, and psy-
chosocial development. After stratification for age and body
mass index (BMI), childrenwere randomly assigned to either the
GH treatment group or the control group for 2 yr.
Follow-up during 4 yr of continuous GH treatment
After the RCT, all children were treated with GH and fol-
lowed in the Dutch PWS Cohort Study. To investigate the effect
of long-termGH treatment on cognition, we analyzed their data
from the start of GH treatment until after 4 yr of GH treatment.
Children who had been in the control group of the RCTwere on
average 2 yr older at the start of GH treatment than those who
had been in the treatment group of the RCT. Two children
droppedout of the cohort study—oneduring the first year ofGH
treatment because of family problems, and the other during the
thirdyearofGHtreatmentbecauseof veryhigh IGF-I levels, even
with a lowGH dose. The data of these children were included in
our analysis until they dropped out.
Biosynthetic GH (Genotropin; Pfizer Inc., New York, NY;
dose, 1.0 mg/m2/d) was administered sc once daily at bedtime in
children of the treatment group during the RCT and in all chil-
dren during the cohort study. All children were naive to GH
treatment at the start of theRCT.During the entire study period,
childrenwere seen 3-monthly for anthropometricmeasurements
by the PWS research team of the Dutch Growth Research Foun-
dation, in collaboration with Dutch pediatric endocrinologists
and pediatricians.
Cognitive functioning was measured biennially during the
RCT and the follow-up during 4 yr of GH treatment. All cog-
nitive measurements described in this study were performed in
the Children’s Hospital Erasmus MC-Sophia by one psycholo-
gist experienced in testing children with PWS. The psychologist
was blinded for the randomization. Missing values occurred be-
cause childrenwere testedby their schoolpsychologist during the
same period; this happened in amaximum of 14%of children at
each time point.
The studyprotocolwas approvedby theMedical EthicsCom-
mittee of the Erasmus MC, Rotterdam, The Netherlands. Writ-
ten informed consent was obtained from the parents and from
children older than 12 yr, and assent was obtained in children
younger than 12 yr of age.
Anthropometry
At baseline and at 3-month intervals, anthropometric mea-
surements were performed. Height was obtained using a
Harpenden stadiometer. Weight was measured on an accurate
scale. Height, weight, BMI, and head circumference were ex-
pressed as SD scores (SDS), adjusting for age and sex (11, 12).
BMI and SDS of BMI, height, weight, and head circumference
were calculated with Growthanalyser, version 3.0 (www.
growthanalyser.org). A detailed description of anthropometric
measurements was previously published (4).
Cognitive functioning
To assess intelligence, a short form of four subtests [Vocab-
ulary, Similarities (verbal IQ subtests), Block design, and Picture
arrangement (performance IQ subtests)] of the Wechsler Intel-
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Medical Center Rotterdam/Sophia Children’s Hospital (E.P.C.S., R.F.A.T.-d.L.v.W., D.A.M.F., G.C.B.B.-d.H., A.C.S.H.-K.), 3015 GJ Rotterdam, The Netherlands; Radboud University Nijmegen
Medical Center (A.A.E.M.v.A.-v.d.V., B.J.O.), 6500 HB Nijmegen, The Netherlands; VU University Medical Center (J.R.), 1081 HV Amsterdam, The Netherlands; St. Catharina Hospital (R.J.H.O.),
5623 EJ Eindhoven, The Netherlands; St. Jansdal Hospital (M.v.L.), 3844 DGHarderwijk, The Netherlands; Diaconessen Hospital (D.A.J.P.H.), 2334 CK Leiden, The Netherlands; Leiden University
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ligence Scale for Children-Revised, Dutch version (WISC-R),
was used in children over 7 yr of age (13). A short form of four
subtests [Vocabulary, Similarities (verbal IQ subtests), Block de-
sign, and Picture completion (performance IQ subtests)] of the
Wechsler Preschool and Primary Scale of Intelligence-Revised,
Dutch version (WPPSI-R) was used for children younger than 7
yr of age (14, 15). We used short forms because of the short
attention span in children with PWS.
Good correlations have been found between the short-form
IQ and the full-scale IQ for both theWISC-R and theWIPPSI-R
(16–18).Wechsler (19) showed that theWPPSI IQ andWISC IQ
are comparable in 6-yr-old children. Three subtests—Vocabu-
lary, Similarities, and Block design—were the same in the
WISC-R and the WPPSI-R short forms. We therefore combined
the results of these subtests to increase the sample size and cor-
rected for a different type of test in our analyses.
Results of the Picture subtest of both WISC-R and WPPSI-R
short forms had to be analyzed separately for each short form
because this subtest differed between the WISC-R and the
WPPSI-R (Picture arrangement in theWISC-R and Picture com-
pletion in the WPPSI-R short form). This resulted in too small
numbers of patients per test, and we could therefore not analyze
the scores on this subtest.
The scores on all subtests were expressed as SDS, based on
normalized standard scores (s-scores)with ameanof 10, ranging
from 1 (3 SDS) to 19 (3 SDS), based on Dutch population
data for the same age (13, 15). TIQ score was calculated accord-
ing to an equation based on Dutch outpatient population refer-
ence (TIQ 45.3 2.91Vocabulary s-score 2.50 Block
design s-score), as has been used in other studies (7, 8).
Assay
Serum IGF-I levels were measured in one central laboratory
using a immunometric technique on an Advantage Automatic
Chemiluminescence System (Nichols Institute Diagnostics, San
Juan Capistrano, CA). The intraassay coefficient of variation
was 4%, and the interassay coefficient of variation was 6%.
Because of age and sex dependency, IGF-I levels were trans-
formed into SDS (20).
Data analysis
Statistical analyseswereperformedwithSPSS17.0 (SPSS Inc.,
Chicago, IL).
Independent samples t testswereused to compare thebaseline
characteristics between the GH-treated patients and the un-
treated controls.
Toanalyze the effect ofGHtreatment during theRCTand the
longitudinal study, LinearMixedModels (21)was usedwithGH
treatment and time as factors (GH treatment coded as: 1GH-
treatment group, and 0  control group; time coded as: 1 
baseline; 2 after 2 yr of study) in theRCTand time (time coded
as: 1  baseline, 2  after 2 yr of GH treatment, 3  after 4 yr
of GH treatment) as the factor in the longitudinal study.
All subtest scores and TIQ scores were corrected for test type
(WPPSI-R orWISC-R) age, gender, and genotype. The effects of
age at the start of GH treatment, gender, genotype, serum IGF-I
level, head circumference, and baseline scores on cognitive func-
tioning during GH treatment were determined by using these
variables as factors (in case of nominal or ordinal variables) or
covariates (in case of scale variables) in the model.
Results
Randomized controlled trial
Baseline characteristics
Fifty prepubertal children with PWS (21 boys, 29 girls)
were included (Table 1). At the start of the RCT, themean
(SD) age was 7.4 (2.5) yr in the treatment group and 6.4
(2.2) yr in the control group (P  0.2). Children had a
baseline height and head circumference significantly be-
low 0 SDS (P  0.0001 for both) and low IGF-I levels.
Twenty children (40%) had a deletion of chromosome
15q11-q13, 19 (38%)hadamUPD,and five (10%)hadan
imprinting center defect (ICD). Positive methylation test
wasdemonstrated in the remaining six (12%)patients, but
the underlying genetic defect was not identified. There
were no significant differences between the treated and
untreated controls at baseline.
Effect of GH treatment vs. no treatment on cognitive
functioning
Figure 1 shows the mean subtest scores and mean TIQ
score at baseline and after 2 yr of study of GH-treated vs.
randomized controlswith PWS.At baseline, therewere no
significant differences in subtest SDS and TIQ scores be-
tween the treatment group and the controls.
After 2 yr of study, mean SDS on all subtests and mean
TIQ score remained similar compared with baseline in
GH-treated children with PWS, indicating that the devel-
opment of cognitive functioning and TIQ score of GH-
treated children with PWS, measured by Similarities,
Block design, and Vocabulary subtests, took place at a
similar pace as inhealthy references. Inuntreated controls,
however, mean subtest SDS and TIQ score were lower
compared with baseline after 2 yr of study. This decrease
was significant for the Similarities and Vocabulary sub-
tests [mean difference (95% confidence interval; CI) be-
tween baseline and after 2 yr of study,0.7 (1.3 to 0.03)
TABLE 1. Baseline characteristics at start of the RCT
GH-treated
Untreated
controls
P
value
n 29 21
Age (yr) 7.4 2.5 6.4 2.2 0.165
Height SDS 2.2 1.4 2.4 1.1 0.540
Weight for height SDS 1.4 1.3 1.6 1.0 0.624
BMI SDS 1.2 1.1 1.4 0.8 0.439
Head circumference SDS 0.7 1.0 0.6 0.8 0.742
IGF-I SDS 1.7 1.1 1.9 1.0 0.504
Genetic cause
Deletion 13 7
UPD 9 10
ICD 1 1
Unknown 3 3
Data are expressed as mean [SD]. UPD, Uniparental disomy.
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SDS, P  0.04 for Similarities; and 0.7 (1.3 to 0.07)
SDS; P  0.03 for Vocabulary]. Thus, in untreated con-
trols, there was a significant deterioration of certain cog-
nitive skills and a nonsignificant deterioration of TIQ
compared with healthy references.
After 2 yr of study, we found no significant differences
between the subtest scores and TIQ scores of the GH-
treated children and the control group, probably due to
the large variation in subtest scores and TIQ scores within
each group.
Long-term GH treatment
Fifty prepubertal children, originally included in the
RCT, were followed during 4 yr of continuous GH treat-
ment. Theirmean (SD) age at the start ofGH treatmentwas
7.8 (2.4) yr.
Cognitive functioning during long-termGH treatment
Figure 2 shows the longitudinal data during 4 yr of GH
treatment. After 4 yr of GH treatment, mean SDS on the
Similarities and Block design subtests were significantly
higher than at baseline [mean difference (95% CI) be-
tweenbaseline andafter 4 yr ofGHtreatment,0.4 (0.1
to 0.7) SDS, P  0.01 for Similarities; and 0.3 (0.07 to
0.6) SDS,P0.01, for Blockdesign], indicating that long-
term GH treatment had significantly improved abstract
verbal reasoning (Similarities subtest) and visuospatial
skills (Block design subtest) and had reduced the gap be-
tween children with PWS and healthy controls on these
skills.
Mean SDS on the Vocabulary subtest remained un-
changed. Thus, during long-term GH treatment, children
with PWS developed their vocabulary at the same pace as
healthy references.Mean estimated TIQ score improved 4
points during 4 yr ofGH treatment. This improvement did
not reach significance (P 0.2), probably due to the large
variation in TIQ scores in children with PWS.
Influence of clinical and genetic characteristics on
cognitive functioning
At baseline, we found significant effects of age at the
start of GH treatment and head circumference SDS on
Block design and Vocabulary SDS and estimated TIQ
FIG. 1. Subtest scores and TIQ score during RCT in GH-treated and untreated children with PWS. This figure shows the mean SDS on the subtests
Similarities (A), Block design (B), and Vocabulary (C), the TIQ score (D), and their 95% CI at baseline and after 2 yr of study in GH-treated children
with PWS (black lines) and untreated controls (gray lines). P values of differences between baseline and after 2 yr of study in the untreated controls
are indicated in gray.
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score. The younger the children were at baseline, the
higher they scored on these subtests and the higher their
TIQ scores (P 0.006,P 0.02, andP 0.005 for Block
design SDS, Vocabulary SDS, and TIQ scores, respec-
tively).We foundacomparable effectof ageonSimilarities
SDS, but this did not reach significance (P  0.08). Chil-
dren with a smaller head circumference SDS scored sig-
nificantly lower on Block design andVocabulary subtests,
and they had significantly lower estimated TIQ scores
than childrenwho had a head circumference in the normal
range compared with Dutch references (P  0.03, P 
0.04, andP0.02 for Block design,Vocabulary, andTIQ
scores, respectively). After 4 yr of GH treatment, the as-
sociations of age and head circumference SDS with cog-
nitive outcomes were no longer significant.
Genotype had a significant effect on Block design SDS
at baseline, and also after correction for age at the start of
GH treatment and head circumference SDS. Scores were
significantly lower in children with anmUPD than in chil-
dren with a deletion genotype (P  0.01). During 4 yr of
GH treatment, children with mUPD showed a significant
catch-up on the Block design subtest score comparedwith
baseline (P 0.05), and after 4 yr, the difference between
deletion and mUPD genotype was no longer significant
(Fig. 3). Children with an ICD genotype showed a com-
parable pattern as children with mUPD, but the differ-
ences were not significant due to the small number of chil-
dren with an ICD.We found no effects of genotype on the
other subtests or TIQ score.
There were no significant effects of serum IGF-I levels,
height, weight, BMI, and gender on any subtest scores or
TIQ score, either at baseline or after 4 yr ofGH treatment.
Influence of baseline scores on cognitive functioning
We found a significant effect of baseline SDS on the
changes in Similarities and Block design subtest scores
FIG. 2. Cognitive development during 4 yr of continuous GH treatment. This figure shows the mean SDS on the subtests Similarities (A), Block design
(B), and Vocabulary (C), and the TIQ score (D) and their 95% CI during 4 yr of continuous GH treatment in children with PWS. Significant P values of
differences between baseline and after 4 yr of GH treatment are indicated. Scores are the mean subtest scores and TIQ score of all children at the start of
GH treatment. Thus, for children in the treatment group of the RCT, these are the subtest scores and TIQ score at the start of the RCT, and for children in
the untreated control group these are the subtest scores and TIQ score at the end of the RCT.
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from baseline to 4 yr of GH treatment. Children with the
lowest scores at baseline showed the highest catch-up in
SDS (P 0.04 and P 0.0001 for Similarities and Block
design, respectively).
After correction for baseline scores, we found no effect
of age at the start of GH treatment, gender, genotype, 
head circumference (0–4 yr), and  IGF-I (0–4 yr) on the
change in subtest and TIQ scores.
Discussion
Our study is the first to describe the effect ofGH treatment
on cognitive functioning in children with PWS during a
2-yr randomized controlled trial andduringGHtreatment
for 4 yr. Our results demonstrate that GH treatment pre-
vents deterioration of certain cognitive skills on the short
term and significantly improves abstract verbal reasoning
and visuospatial skills during 4 yr of GH treatment. Chil-
dren with an mUPD started off with significantly lower
visuospatial skills but showed a larger improvement on
these skills after 4 yr of GH treatment than children with
a deletion genotype. Furthermore, in children with lower
cognitive functioning at baseline, GH treatment had a
greater effect on abstract verbal reasoning and visuospa-
tial skills.
There is only one other study reporting the effect ofGH
treatment on cognition in children (age	 3 yr) with PWS
(22). The authors could not find an effect, but this might
be due to their small patient number (n  12) and short
period of GH treatment (6months). Studies in infants and
adults with PWS did show an effect of GH treatment on
cognition (5, 6, 23), as did studies in children with GH
deficiency (24), children born small for gestational age (7,
8), and children with Down syndrome (9).
Our findings show that GH treatment improves ab-
stract verbal reasoning and visuospatial skills in children
with PWS. This is in line with other studies showing that
GH treatment can influence spatial skills. In GH-deficient
adults, GH treatment prevented spatial memory impair-
ment (25), and in hypophysectomized rats, spatial perfor-
mance was significantly better in GH-treated than in un-
treated animals (26).
It is known that GH receptors are located throughout
the brain and that GH and IGF-I affect the genesis of neu-
rons, astrocytes, endothelial cells, and oligodendrocytes
(27). Recently, GH treatment has been shown to induce
cell genesis in the adult brain (28). Furthermore, GH in-
creases connexin-43 expression (aubiquitousbiochemical
marker for gap-junction formation in the brain) in the
cerebral cortex and the hypothalamus, thereby enhancing
cell to cell communication in the central nervous system
(29).We found no relation between cognitive functioning
and IGF-I levels, andas far asweknow, sucha relationship
has not been found in other studies regarding the effect of
GH treatment on cognitive functioning in children. This
suggests that the effect of GH on cognitive functioning in
PWS might be paracrine in the brain. It has indeed been
shown that GH has many effects in the central nervous
systemthat are independentof serumIGF-I levels (30–32).
The effects of GH treatment we demonstrated in our RCT
and long-term study in childrenwith PWS, in combination
with the findings listed above, indicate plasticity of the
human brain and the local activity of GH and IGF-I.
Another explanation for the improved cognitive skills
during GH treatment could be that there is a relation with
sleep-related breathing disorders in children with PWS. A
few years ago, we studied sleep-related breathing during
GH treatment in children with PWS (33) and found a
nonsignificant decrease of the Apnea Hypopnea index af-
ter 6 months of GH treatment. However, because we did
not find any significant relationbetween cognition and the
central or obstructive apnea index in untreated children
with PWS in another study (34), it seems unlikely that the
improved cognitive performance is the result of less sleep-
related breathing disorders.
Before the start of GH treatment, older age had a
significant negative effect on cognition. Also, untreated
controls showed a deterioration of cognitive function-
ing. These findings indicate that cognitive functioning
of untreated children with PWS deteriorates over time
compared with healthy children. Our study shows that
GH treatment prevents this deterioration. As a result,
the relation between age and cognition was no longer
significant after 4 yr of GH treatment. In addition, we
FIG. 3. Block design SDS per genotype at baseline and after 4 yr of
GH treatment. This figure shows the mean SDS at baseline and after 4
yr of continuous GH treatment on the Block design subtest for children
with deletion, mUPD, and ICD separately. The significant P values of
the differences between the scores of children with different
genotypes and between scores at baseline and after 4 yr of GH
treatment are indicated.
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found that baseline scores had a significant effect on the
change in scores on the Similarities and Block design
subtests during GH treatment. It appeared that GH treat-
ment was most beneficial for children with the lowest
scores. Baseline scores were even more important for the
degree of catch-up in cognitive skills than age at the start
ofGHtreatment, gender, genotype,head circumference,
or  IGF-I. Our findings might suggest that GH should
best be administered at an early age to prevent deteriora-
tion of cognitive functioning in children with PWS, but
that GH treatment also induces a catch-up in cognitive
skills in children with PWS who lag behind, even when
they start at an older age.
Before the start of GH treatment, children with a de-
letion genotype scored better on the Block design subtest
than children with mUPD. Comparable differences be-
tween genetic subtypes of PWS have been noted in other
studies. The deletion genotype is associated with better
performance IQ scores and the mUPD genotype with bet-
ter verbal IQ scores (35). A recent study investigated dor-
sal and ventral stream-mediated visual processing in PWS
(36). They found that children with a deletion genotype,
but not children with an mUPD genotype, had a relative
strength in visual processing in the ventral stream. This
might explain the difference in baseline Block design test
scores between the childrenwith a deletion and thosewith
mUPD.
In most studies, patients with PWS are described as
having a mild-to-moderate learning disability with a TIQ
score below 70 (23, 35). At baseline, the majority of the
children in our study had indeed a TIQ score below 70,
comparable towhat is found inother studies.During long-
term GH treatment, the mean TIQ score increased, al-
though not significantly, from 66 at baseline to 70 after 4
yr of GH treatment, meaning that at this point only half of
the childrenwith PWS in our studywill be diagnosedmen-
tally retarded according to the DSM-IV. In another study
investigating the effects of GH treatment on cognition in
children born small for gestational age after 2 and 8 yr,
authors found a significant increase of 0.7 SDS on the
Block Design subtest and of 7 points on TIQ score over a
period of 8 yr of GH treatment (8). After 2 yr, there was
already a positive but nonsignificant effect of GH treat-
ment on cognition, which increased in the subsequent 6 yr
to the significant improvement at 8 yr after the start ofGH
treatment.
These andourdatamight suggest that the improvement
of cognitive functioning during GH treatment becomes
larger over time. As a result, the clinical effects become
clearerwith longer duration ofGH treatment, especially if
one keeps in mind that untreated children with PWS have
a deterioration of cognitive functioning as shown in the
RCT. The effects of GH treatment on cognitive skills in
children with PWS would probably have been more sig-
nificant if we could have studied a much larger group.
However, PWS is a rare disorder, and in the present study
we evaluated a relatively large group of children with
PWS.
Next to the increase in TIQ score, parents did not
report an increase in behavioral problems or food seek-
ing behavior during GH treatment. They rather re-
ported a decrease in problem behavior, but this needs
further investigation.
Mean subtest scores on all subtests, except Block de-
sign, were in the normal range compared with healthy
children (higher than2 SDS) during the entire long-term
study. Themean score on Block designwas below2 SDS
at baseline, but after 4 yr of GH treatment, themean score
on Block design SDS was also in the normal range. This
points out that the increase in TIQ score was mostly due
to the increase on Block design score, a performance test.
Our study shows that GH treatment prevents dete-
rioration of certain cognitive skills in childrenwith PWS
in the short term and significantly improves abstract
verbal reasoning and visuospatial skills during 4 yr of
GH treatment compared with a reference population.
The more children lag behind, the more they benefit
from GH treatment. Based on our results, we conclude
that GH treatment in children with PWS is not merely
an effective treatment for normalizing height and im-
proving body composition, but it also has a beneficial
effect on their cognitive functioning.
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